Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1304-1308

  Walker, Alison R ^a   Klisovic, Rebecca B ^a   Garzon, Ramiro ^a   Schaaf, Larry J ^b   Humphries, Kristina ^b   Devine, Steven M ^a   Byrd, John C ^a   Grever, Michael R ^a   Marcucci, Guido ^a,b   Blum, William ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Azacitidine; Bortezomib; Relapsed AML

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; AZACITIDINE; BORTEZOMIB; CYTARABINE; TROPONIN I; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ACIDOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INDUCTION CHEMOTHERAPY; INFECTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIMB PAIN; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; BONE MARROW; CLINICAL TRIAL; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BONE MARROW; BORONIC ACIDS; FEMALE; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; TREATMENT OUTCOME;

EID: 84901301291     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.833333     Document Type: Article

References (28)

1. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients wiThacute myeloid leukemia in fi rst relapse. JClin Oncol 2005; 23: 1969-1978. (Pubitemid 46211376
2. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612
3. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive signifi cance in older AML patients treated wiTha 10-Day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 7473-7478
4. Blum W, Klisovic R B, Hackanson B, et al. Phase I study of decitabine alone or in combination wiThvalproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884-3891. (Pubitemid 47477265
5. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the fi rst-line treatment of older patients wiThacute myeloid leukemia. JClin Oncol 2009; 28: 556-561
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared wiThconventional care regimens in elderly patients wiThlow bone marrow blast count acute myeloid leukemia. JClin Oncol 2009; 28: 562-569
7. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-Dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2'-Deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-1640. (Pubitemid 38268953
8. Garcia-Manero G, Kantarjian H M, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-Aza-2'-Deoxycytidine wiThvalproic acid in patients wiThleukemia. Blood 2006; 108: 3271-3279
9. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361-6369
10. Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering wiThSp1/NF-kappaBdependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111: 2364-2373. (Pubitemid 351451445
11. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012; 21: 6025-6031
12. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039
13. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in fi rst relapse: A comprehensive review of the literature. Leuk Lymphoma 2002; 43: 1715-1727. (Pubitemid 34874002
14. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062. (Pubitemid 29451802
15. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older wiThacute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 2006; 106: 1090-1098
16. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients wiThAML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598-605
17. Li LH, Olin EJ, Buskirk HH, et al. Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res 1970; 30 : 2760-2769
18. Aimiuwu J, Wang H, Chen P, et al. RNA-Dependent inhibition of ribonucleotide reductase is a major pathway for 5-Azacytidine activity in acute myeloid leukemia. Blood 2012; 119: 5229-5238
19. Al-Ali H K, Jaekel N, Junghanss C, et al. Azacitidine in patients wiThacute myeloid leukemia medically unfi t for or resistant to chemotherapy: A multicenter phase I/II study. Leuk Lymphoma 2012; 53: 110-117
20. Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients wiThacute myeloid leukemia: Report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012; 118 : 1014-1022
21. Borthakur G, Huang X, Kantarjian H, et al. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 2010; 51: 73-78
22. Raff oux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-Azacitidine, valproic acid, and all-Trans retinoic acid in patients wiThhigh-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010; 1: 34-42
23. Ramsingh G, Westervelt P, Cashen A F, et al. Aphase 1 study of concomitant high-Dose lenalidomide and 5-Azacitidine induction in the treatment of AML. Leukemia 2013; 27: 725-728
24. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-Azacytidine, valproic acid, and all-Trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302-2308. (Pubitemid 47523148
25. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients wiThrelapsed or refractory follicular or marginal-zone B-cell lymphoma. JClin Oncol 2009; 27: 5023-5030
26. Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009; 146: 652-655
27. HainsworthJD, Spigel DR, Barton J, et al. Weekly treatment wiThbortezomib for patients wiThrecurrent or refractory multiple myeloma: A phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 113: 765-771
28. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients wiThrelapsed multiple myeloma: Arandomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-440